The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Benfield, P., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632040-00002 · Cited by 494
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
Self-citationEvidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Jerling, M., Lindström, L., Bondesson, U., & Bertilsson, L. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199408000-00006 · Cited by 281
Wrighton, S. A., Stevens, J. C., Becker, G. W., & Vandenbranden, M. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1506 · Cited by 281
Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.
Sesardic, D., Boobis, A., Murray, B., Murray, S., Segura, J., de la Torre, R., & Davies, D. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03686.x · Cited by 278
Bertilsson, L., Henthorn, T. K., Sanz, E., Tybring, G., Säwe, J., & Villén, T. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.40 · Cited by 249
Sindrup, S. H., Brøsen, K., Hansen, M. G. J., Aaes-Jørgensen, T., Overø, K. F., & Gram, L. F. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199302000-00002 · Cited by 213
Self-citation
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Human Pharmacology of MDMA: Pharmacokinetics, Metabolism, and Disposition
de la Torre, R., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., & Camí, J. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00009 · Cited by 444
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., & Tremaine, L. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093229 · Cited by 433
Clinically Significant Pharmacokinetic Interactions Between Dietary Caffeine and Medications
Carrillo, J. A., & Benitez, J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039020-00004 · Cited by 364
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
Madlensky, L., Natarajan, L., Tchu, S., Pu, M., Mortimer, J., Flatt, S. W., Nikoloff, D. M., Hillman, G., Fontecha, M. R., Lawrence, H. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.32 · Cited by 334
Wormhoudt, L. W., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Critical Reviews in Toxicology · doi:10.1080/10408449991349186 · Cited by 302
Depression in Epilepsy: Etiology, Phenomenology, and Treatment
Lambert, M. V., & Robertson, M. M. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00884.x · Cited by 293
Pharmacokinetics of Haloperidol
Froemming, J. S., Lam, Y. W. F., Jann, M. W., & Davis, C. M. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198917060-00004 · Cited by 291
Bernard, S., Neville, K. A., Nguyen, A. T., & Flockhart, D. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-126 · Cited by 277
Scott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J.-S., Thorn, C. F., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834d4962 · Cited by 261
Gunes, A., & Dahl, M.-L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.625 · Cited by 256
An overview of tramadol and its usage in pain management and future perspective
Subedi, M., Bajaj, S., Kumar, M. S., & YC, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.085 · Cited by 230
Melatonin Interaction Resulting in Severe Sedation
Foster, B. C., Cvijovic, K., Boon, H. S., Tam, T. W., Liu, R., Murty, M., Vu, D., Jaeger, W., Tsuyuki, R. T., Barnes, J., et al. (2015) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3ss35 · Cited by 17
Cheer, S. M., & Figgitt, D. P. (2001) · Paediatric Drugs · doi:10.2165/00128072-200103100-00004 · Cited by 15
General Principles of Pharmacokinetics
Preskorn, S. H., & Catterson, M. L. (2004) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-18500-7_2 · Cited by 14
Metadata
- Authors
- Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., & Brøsen, K.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 1996-09-02
- Volume
- 51
- Issue
- 1
- Pages
- 73-78
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2045654730
- Cited by
- 321
- References
- 31
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.